Antimalarial drug resistance.

By N. White. Journal of Clinical Investigation, 2004

1,244 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Artemisinin-based combination treatment of falciparum malaria. (2007, background): “combination still provides good protection against the emergence of resistance to the partner drug, but once resistance has developed the residual concentrations of unprotected partner drug do provide a selective filter enhancing the spread of resistance to the partner compound.(7,8) Figure 2 shows ”
Malaria: progress, perils, and prospects for eradication. (2008, positive): “…first-line antimalarials chloroquine and sulfadox-ine-pyrimethamine (53–55) has had a devastating impact on malaria treatment and control and has spurred multiple investigations into the development of new antimalarials, with an emphasis on artemis-inin-based combination therapies (ACTs) (56, 57).”
A Systematic Map of Genetic Variation in Plasmodium falciparum (2006, positive): “Drug Resistance While single point mutations in drug targets and receptors, which may not be identified by our analysis, can result in drug resistance, evidence suggests in some cases that multiple mutations are associated with resistance [44].”